Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
Год журнала:
2022,
Номер
1868(12), С. 166557 - 166557
Опубликована: Сен. 24, 2022
Lung
cancer
is
the
most
malignant
human
worldwide,
also
with
highest
incidence
rate.
However,
small-cell
lung
(SCLC)
accounts
for
14
%
of
all
cases.
Approximately
10
patients
SCLC
have
brain
metastasis
at
time
diagnosis,
which
leading
cause
death
worldwide.
The
median
overall
survival
only
4.9
months,
and
a
long-tern
cure
exists
due
to
limited
common
therapeutic
options.
Recent
studies
enhanced
our
understanding
molecular
mechanisms
meningeal
metastasis,
multimodality
treatments
brought
new
hopes
better
disease.
This
review
aimed
offer
an
insight
into
cellular
processes
different
metastatic
stages
revealed
by
established
animal
models,
major
diagnostic
methods
SCLC.
Additionally,
it
provided
in-depth
information
on
recent
advances
in
treatments,
highlighted
several
models
biomarkers
promises
improve
prognosis
Cell,
Год журнала:
2020,
Номер
182(1), С. 200 - 225.e35
Опубликована: Июль 1, 2020
To
explore
the
biology
of
lung
adenocarcinoma
(LUAD)
and
identify
new
therapeutic
opportunities,
we
performed
comprehensive
proteogenomic
characterization
110
tumors
101
matched
normal
adjacent
tissues
(NATs)
incorporating
genomics,
epigenomics,
deep-scale
proteomics,
phosphoproteomics,
acetylproteomics.
Multi-omics
clustering
revealed
four
subgroups
defined
by
key
driver
mutations,
country,
gender.
Proteomic
phosphoproteomic
data
illuminated
downstream
copy
number
aberrations,
somatic
fusions
identified
vulnerabilities
associated
with
events
involving
KRAS,
EGFR,
ALK.
Immune
subtyping
a
complex
landscape,
reinforced
association
STK11
immune-cold
behavior,
underscored
potential
immunosuppressive
role
neutrophil
degranulation.
Smoking-associated
LUADs
showed
correlation
other
environmental
exposure
signatures
field
effect
in
NATs.
Matched
NATs
allowed
identification
differentially
expressed
proteins
diagnostic
utility.
This
proteogenomics
dataset
represents
unique
public
resource
for
researchers
clinicians
seeking
to
better
understand
treat
adenocarcinomas.
Journal of Clinical Oncology,
Год журнала:
2022,
Номер
40(6), С. 611 - 625
Опубликована: Янв. 5, 2022
Lung
cancer
has
traditionally
been
classified
by
histology.
However,
a
greater
understanding
of
disease
biology
and
the
identification
oncogenic
driver
alterations
dramatically
altered
therapeutic
landscape.
Consequently,
new
classification
paradigm
non-small-cell
lung
is
further
characterized
molecularly
defined
subsets
actionable
with
targeted
therapies
treatment
landscape
becoming
increasingly
complex.
This
review
encompasses
current
standards
care
for
in
molecular
alterations.
Targeted
EGFR
exon
19
deletion
L858R
mutations,
ALK
ROS1
rearrangements
are
well
established.
there
an
expanding
list
approved
including
BRAF
V600E,
20
insertion,
KRAS
G12C
MET
14
alterations,
NTRK
RET
rearrangements.
In
addition,
numerous
other
drivers,
such
as
HER2
insertion
which
emerging
efficacy
data
therapies.
The
importance
diagnostic
testing,
intracranial
novel
therapies,
optimal
sequencing
role
early-stage
disease,
future
directions
precision
oncology
approaches
to
understand
tumor
evolution
resistance
also
discussed.
Nature Communications,
Год журнала:
2020,
Номер
11(1)
Опубликована: Окт. 16, 2020
Abstract
The
Human
Proteome
Organization
(HUPO)
launched
the
Project
(HPP)
in
2010,
creating
an
international
framework
for
global
collaboration,
data
sharing,
quality
assurance
and
enhancing
accurate
annotation
of
genome-encoded
proteome.
During
subsequent
decade,
HPP
established
collaborations,
developed
guidelines
metrics,
undertook
reanalysis
previously
deposited
community
data,
continuously
increasing
coverage
human
On
occasion
HPP’s
tenth
anniversary,
we
here
report
a
90.4%
complete
high-stringency
proteome
blueprint.
This
knowledge
is
essential
discerning
molecular
processes
health
disease,
as
demonstrate
by
highlighting
potential
roles
plays
our
understanding,
diagnosis
treatment
cancers,
cardiovascular
infectious
diseases.
Molecules and Cells,
Год журнала:
2021,
Номер
44(7), С. 433 - 443
Опубликована: Июль 1, 2021
Multi-omics
approaches
are
novel
frameworks
that
integrate
multiple
omics
datasets
generated
from
the
same
patients
to
better
understand
molecular
and
clinical
features
of
cancers.A
wide
range
emerging
multiview
clustering
algorithms
now
provide
unprecedented
opportunities
further
classify
cancers
into
subtypes,
improve
survival
prediction
therapeutic
outcome
these
key
pathophysiological
processes
through
different
layers.In
this
review,
we
overview
concept
rationale
multi-omics
in
cancer
research.We
also
introduce
recent
advances
development
integration
methods
for
multiple-layered
patients.Finally,
summarize
latest
findings
large-scale
studies
various
their
implications
patient
subtyping
drug
development.
Cell,
Год журнала:
2021,
Номер
184(7), С. 1661 - 1670
Опубликована: Апрель 1, 2021
When
it
comes
to
precision
oncology,
proteogenomics
may
provide
better
prospects
the
clinical
characterization
of
tumors,
help
make
a
more
accurate
diagnosis
cancer,
and
improve
treatment
for
patients
with
cancer.
This
perspective
describes
significant
contributions
The
Cancer
Genome
Atlas
Clinical
Proteomic
Tumor
Analysis
Consortium
oncology
makes
case
that
needs
be
fully
integrated
into
trials
patient
care
in
order
deliver
right
cancer
at
dose
time.
Nature Communications,
Год журнала:
2021,
Номер
12(1)
Опубликована: Авг. 16, 2021
Abstract
Esophageal
cancer
(EC)
is
a
type
of
aggressive
without
clinically
relevant
molecular
subtypes,
hindering
the
development
effective
strategies
for
treatment.
To
define
subtypes
EC,
we
perform
mass
spectrometry-based
proteomic
and
phosphoproteomics
profiling
EC
tumors
adjacent
non-tumor
tissues,
revealing
catalog
proteins
phosphosites
that
are
dysregulated
in
ECs.
The
cohort
stratified
into
two
subtypes—S1
S2—based
on
analysis,
with
S2
subtype
characterized
by
upregulation
spliceosomal
ribosomal
proteins,
being
more
aggressive.
Moreover,
identify
signature
composed
ELOA
SCAF4,
construct
diagnostic
prognostic
model.
Potential
drugs
predicted
treating
patients
subtype,
three
candidate
validated
to
inhibit
EC.
Taken
together,
our
analysis
thus
providing
potential
therapeutic
outlook
improving
disease
outcomes
